Literature DB >> 10892838

Expression of epidermal growth factor receptor: risk factor in uveal melanoma.

H M Hurks, J A Metzelaar-Blok, E R Barthen, A H Zwinderman, D De Wolff-Rouendaal, J E Keunen, M J Jager.   

Abstract

PURPOSE: To investigate the prognostic significance of the expression of epidermal growth factor receptor (EGFR) in uveal melanoma. EGFR is a transmembrane glycoprotein, and its expression has been correlated with the development of metastases in various malignancies.
METHODS: Frozen sections from 22 primary uveal melanomas were examined for EGFR expression by a three-step immunoperoxidase staining, using a mouse anti-human EGFR IgG2b monoclonal antibody. The results were compared with patient survival and clinical and histopathologic parameters.
RESULTS: EGFR expression could not be determined on one tumor due to excessive pigmentation. Two patients died of causes unrelated to melanoma, and two patients were lost to follow-up. Out of 21 tumors, six tumors showed immunoreactivity for EGFR. Five of these six patients (83%) died due to metastases, compared with 2 (17%) of 12 patients with no EGFR expression (Kaplan-Meier analysis P = 0.0004). EGFR-positive tumors tended to have a greater tumor prominence and a higher mitotic rate.
CONCLUSIONS: The expression of EGFR was significantly correlated with death due to metastatic disease and therefore can be regarded as an important prognostic factor in human uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892838

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Delayed systemic recurrence of uveal melanoma.

Authors:  Nathalie A Kolandjian; Caimiao Wei; Sapna P Patel; Jessica L Richard; Tina Dett; Nicholas E Papadopoulos; Agop Y Bedikian
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

2.  Single-cell tumor dormancy model of uveal melanoma.

Authors:  Patrick T Logan; Bruno F Fernandes; Sebastian Di Cesare; Jean-Claude A Marshall; Shawn C Maloney; Miguel N Burnier
Journal:  Clin Exp Metastasis       Date:  2008-03-12       Impact factor: 5.150

3.  Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3.

Authors:  S Hughes; B E Damato; I Giddings; P S Hiscott; J Humphreys; R S Houlston
Journal:  Br J Cancer       Date:  2005-11-14       Impact factor: 7.640

4.  The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.

Authors:  Wenying Shu; Xue Zhu; Ke Wang; Svetlana Cherepanoff; R Max Conway; Michele C Madigan; Hong Zhu; Ling Zhu; Michael Murray; Fanfan Zhou
Journal:  Cell Oncol (Dordr)       Date:  2022-07-04       Impact factor: 7.051

5.  Prognostic value of receptor tyrosine kinases in malignant melanoma patients: A systematic review and meta-analysis of immunohistochemistry.

Authors:  Xuan Lei; Yiming Zhang; Lianghao Mao; Pan Jiang; Yumeng Huang; Jia Gu; Ningzheng Tai
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development.

Authors:  W Zuidervaart; P A van der Velden; M H Hurks; F A van Nieuwpoort; C J J Out-Luiting; A D Singh; R R Frants; M J Jager; N A Gruis
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.